Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Urology, Haga Hospital, The Hague, The Netherlands.
Fam Pract. 2021 Jun 17;38(3):292-298. doi: 10.1093/fampra/cmaa116.
Adverse drug reactions on sexual functioning (sADRs) may seriously decrease a person's quality of life. A multitude of diseases and drugs are known risk factors for sexual dysfunction. To inform patients better about these potential effects, more insight is needed on the estimated number of patients at high risk for sADRs and their characteristics.
This cross-sectional study estimated the number of patients in the Netherlands who were dispensed drugs with a potential very high risk (>10%) or high risk (1-10%) for sADRs as registered in the Summary of Product Characteristics, the official drug information text in Europe.
In April 2019, 2.06% of the inhabitants of the Netherlands received drugs with >10% risk for sADRs and 7.76% with 1-10% risk. The majority of these patients had at least one additional risk factor for decreased sexual function such as high age or depression. Almost half of the patients were identified with two or more morbidities influencing sexual functioning. Paroxetine, sertraline and spironolactone were the most dispensed drugs with a potential >10% risk for sADRs. One-third of their first dispenses were not followed by a second dispense, with a higher risk of discontinuation for a decreasing number of morbidities.
About 1 in 11 inhabitants of the Netherlands was dispensed a drug with a potential high risk for sADRs, often with other risk factors for sexual complaints. Further research is needed whether these users actually experience sADRs, to understand its impact on multimorbid patients and to provide alternatives if needed.
药物引起的性功能障碍（sADR）可能会严重降低一个人的生活质量。许多疾病和药物是已知的性功能障碍的危险因素。为了让患者更好地了解这些潜在影响，需要更多地了解潜在的 sADR 高风险患者的数量及其特征。
本横断面研究估计了荷兰有多少患者被开了具有潜在极高风险（>10%）或高风险（1-10%）的药物，这些药物的 sADR 风险已在产品特性摘要中登记，这是欧洲官方的药物信息文本。
2019 年 4 月，荷兰有 2.06%的居民服用了具有>10%的 sADR 风险的药物，7.76%的居民服用了具有 1-10%的 sADR 风险的药物。这些患者中的大多数至少还有其他一个导致性功能下降的风险因素，如高龄或抑郁。几乎一半的患者被诊断出患有两种或两种以上影响性功能的疾病。帕罗西汀、舍曲林和螺内酯是最常被开出的具有潜在>10%的 sADR 风险的药物。他们的首次配药中有三分之一没有第二次配药，随着合并症数量的减少，停药的风险更高。
荷兰约有 1/11 的居民被开出了具有潜在高风险的 sADR 的药物，这些药物通常还伴有其他性功能障碍的风险因素。需要进一步研究这些患者是否真的出现了 sADR，以了解其对多病共存患者的影响，并在必要时提供替代药物。
